Exact Sciences to Participate in September Investor Conferences

Exact Sciences to Participate in September Investor Conferences

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

  • Wells Fargo Healthcare Conference, Boston
    Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET
  • Baird Global Healthcare Conference, New York
    Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET

The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com .

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com , follow Exact Sciences on X @ExactSciences , or find Exact Sciences on LinkedIn and Facebook .

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

News Provided by Business Wire via QuoteMedia

EXAS:US
The Conversation (0)
Exact Sciences Corporation

Exact Sciences Corporation

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.

Latest Press Releases

Related News

×